Despite life for many returning to something a little more “normal” since the Covid-19 pandemic took hold in 2019, the number of cancer patients with covid comorbidity continues to rise. Management strategies for these affected patients are urgently needed.
Now, Maichan Lau, Joe YEONG 杨宝诚 and colleagues at the Institute of Molecular and Cell Biology, Duke-NUS Medical School, Singapore General Hospital, Cancer Science Institute of Singapore and the National Cancer Centre Singapore, have reported their initial findings on how SARS-CoV-2 infection might impact on cancer patients and their treatment.
Leveraging a spatial whole-transcriptomics analysis approach, the researchers found that SARS-CoV-2 infection might induce a persistent, immunological memory that could offer tissue-level protection against reinfection and perhaps even modulate the tumour microenvironment to favour immune checkpoint blockade responses!
Find out more in their paper published earlier this year in Frontiers in Immunology:
Congratulations to this great team based in Singapore for this highly relevant and impactful work!